Cypherpunk Grows Zcash Treasury to 314,185.70 ZEC and Secures Sirexatamab Fast Track
Cypherpunk Technologies increased its Zcash treasury holdings to 314,185.70 ZEC after purchasing 10,279.30 ZEC for $5 million and invested $5 million in Zcash Open Development Labs. Leap Therapeutics’ sirexatamab secured FDA Fast Track designation following a Phase 2 study showing 42% ORR and HR 0.47 in DKK1-high colorectal cancer.
1. Zcash Treasury Growth and Investment
Cypherpunk increased its Zcash treasury to 314,185.70 ZEC, acquiring an additional 10,279.30 ZEC for $5 million at an average price of $486.41 per ZEC, bringing its average cost basis to $337.86 and representing 1.88% of the total Zcash supply. The company also committed $5 million to Zcash Open Development Labs to support wallet and protocol development.
2. Leap Therapeutics Clinical Progress
Subsidiary Leap Therapeutics received FDA Fast Track designation for sirexatamab in combination with chemotherapy and bevacizumab for DKK1-high metastatic colorectal cancer. Phase 2 DeFianCe Part B data showed a 42% overall response rate versus 16% in controls (p=0.003) and a hazard ratio of 0.47 for overall survival (p=0.0244) in patients with DKK1 levels above 380 pg/mL.
3. First Quarter Financial Highlights
Net loss widened to $77.2 million in Q1 2026, up from $15.4 million year-over-year, driven by a $77.6 million unrealized loss on Zcash holdings as ZEC fell from $508.09 to $240.47. Research and development expenses dropped to $0.2 million, general and administrative expenses rose to $4.7 million, and cash and equivalents stood at $6.7 million.
4. Investor Dashboard and Website Launch
The company launched a revamped website and real-time investor dashboard providing transparency on key metrics, including Zcash holdings, privacy technology investments, and Zcash network data, aimed at enhancing shareholder visibility into treasury performance and technology developments.